Treatment Resistant Depression (TRD)
21
11
12
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
5%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (21)
Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression
Algorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression
Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Ketogenic Diet and Neuromodulation in Treatment Resistant Depression
Neuronavigated aiTBS for TRD
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression
Ketamine Biomarker Validation
Parcel-guided rTMS for Major Depressive Disorder
Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression
Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression
Intravenous Ketamine for Treatment-Resistant Depression
2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation
Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients
Treatment Resistant Depression and Vagus Nerve Stimulation
Maintenance TMS in Treatment Resistant Depression
Comparison of Different Acceleration Modes of Transcranial Magnetic Stimulation
TACS on High-inflammatory and Refractory Depression
Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.